Exchange: NASDAQ·Updated 07:49 PM EST
GLSI logo

GLSI Greenwich LifeSciences Inc

$19.25
$0.54
(2.73%)
Today
Closed $19.25
$1.20
(6.23%)
After Hours
EarningsMar 31
Mkt Cap$282.56M
Vol472,144.00

About GLSI

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
79

Extremely Bullish Sentiment

How do you feel about GLSI?

Rolltide2020
$GLSI Very favorable asymmetric risk setup right now IMHO. Next week could bring partnership or other non-scientific updates. The following week could also bring those plus explosive scientific data. Worst case is we don’t get those updates yet and it won’t necessarily mean bad news, just no news yet. Just need the broader market to stop sucking.
14
Rolltide2020
$GLSI So SLS market cap is currently around $4B for a drug forecasted to treat up to 4,000 patients per year and forecasted sales up to $500 million per year. GLSI market cap just north of $250 million with a drug expected to treat 88,000 per year and forecasted revenue of $5 to $10 billion per year. Just making sure I got that right.
1
14
RiderInTheSky
$GLSI When I opened my position in GLSI I was also considering SLS & VKTX. I ultimately decided on GLSI favoring Patels leadership qualities & shareholder friendly plus a lot of skin in the game. I hv been burned 🔥 before on management. I am confident with my decision on Patel & his style. Hv added more when it dipped to low $13’s & glad I did !
15
KINGSTOCKERS
$GLSI We have an awesome loyal group here for as long as I can remember, really rooting for the success of this for us all
18
jm4
$GLSI could see a multi day runner into December with $SLS news and conf. Update. Lining up like last year price action
16
telomerase
$GLSI so SLS proved that peptide vaccines can work, after all the failures for decades. Congrats to SLS, and this is certainly a big piece of evidence that Flamingo will be successful as well, both trials are trying to prevent recurrence, apparently an easier task for immunotherapy than a frontal assault on a full-grown cancer.
15
TheinvestmetABCD
$GLSI Great! $SLS buyers will also have a look here and come over. Furthermore, we should get some more media attention and eyes on us soon. I believe we will have some major catalyst soon that will pump the price way higher, either a partnership or really great open label data. The reason is that Snehal did not use any ATM at all in the last Quarter despite running low on cash!
15
Sanibelspeaks
$GLSI no change w my thought at all, not selling for nickels on a day trade, because once news hits w no warning, there will be no time to react 🚀- obviously no guarantees but I feel good about this one
16
Rolltide2020
$GLSI It's fair to debate efficacy since we don't have Phase 3 randomized data yet, but here is how many red flags that would have had to be missed to get to this point:
2
5
Toontje1
$GLSI This is 100% bullish. Patel could have chosen for $$ instead of stock. He does know the data ten times better than us, he knows the safety profile of the patients, talks to doctors who say there are less recurrences in their group of people. This is a goldmine and Patel knows it. Would he play 100% safe and look for a partnership? I would say yes. He knew 1-2-3 years ago probably how and wich partner he would take, but the partner wanted to wait till trial modification. I can be wrong but Patel looks a smart person and better take 70% of the value with 100% safety in stead of 100% of the value with 70% safety.
2
8
crypto_biotech
$GLSI What a day. Hopefully Snehal used the ATM. No one noticed and we are up 35%. Sellas had their day and finished almost 1/3 of what they did. Bodes well for our data. We will do 1000%.
1
9
manuel077
$GLSI $SLS now that SLS cancer vaccine works, glsi is next, we should trade for at least 1B. 4x from here
11
doc123266
$GLSI I have always hated the sls-glsi rivalry. I have always loved some of the similarities. Super stoked for all sls investors.
11
FMSTOCKS01
$GLSI Just saw the Red Chip interview - very impressive and will be buying more. I just can not understand how a company could be valued at less than a billion dollars during a phase 3 trial with a potential blockbuster drug!
11
Waterwing
$GLSI Next up following Bio Europe closed conferences... Snehal Patel and Greenwich LifeSciences are scheduled to present GLSI-100 at the 2026 San Antonio Breast Cancer Symposium (SABCS). Preliminary efficacy and safety results from open-label non-HLA-A02 arm of an ongoing Phase III study of GLSI-100 (GP2 + GM-CSF) in HER2+ breast cancer patients with residual disease or high-risk PCR after both neoadjuvant and postoperative adjuvant anti-HER2 therapy, FLAMINGO-01.* Presenter: Snehal Patel Organization: Greenwich LifeSciences Date: Wednesday, December 9, 2026 Time: 12:30–2:00 p.m. Central Location: Exhibit Hall, Poster Session 1 Official SABCS presentation listing.
11
lowpricedstocks
$GLSI I’m glued to first and second interims. Only thing that makes sense is what Patel said in earlier interview - we’re taking this therapy as far as we can to maximise value for our shareholders. Execs hold 75-80% of shares and no deals or partnerships happening before second interim superiority
1
8
Toontje1
$GLSI I am getting more and more conviction that we truly have gold in our hands. After Phase 3 of Kadcyla, 88.3% of the vaccine group remained free of recurrence, compared to 77% in the placebo group. Honestly, I don't find that so impressive for standard of care… 🤭—it's only a 50% risk reduction. And when you factor in the toxicity that Kadcyla causes on top of that... I completely understand why Patel is only buying and not selling. This is a massive win. No serious side effects like Kadcyla. If Kadcyla can become the standard of care, Greenwich certainly can too. Even with a 50–60% reduction, I still see it becoming the standard of care—though obviously at a much lower price point than if it delivers a 70–80% reduction (which is what it currently looks like it's heading toward)
11
Toontje1
$GLSI begrijpen: A quick lesson on how GLSI-100 actually works. For those wondering why this approach is so revolutionary, let’s look at the actual science and chemistry behind it: 1. It’s not brute force chemo — It’s a targeted software update GLSI-100 (GP2) isn’t a heavy, toxic drug. Chemically, it is a synthetic peptide—a specific, short string of amino acids (amino acids 365–379) derived directly from the HER2 protein found on cancer cells. 2. The Trojan Horse mechanism When injected alongside an immunologic helper (GM-CSF), this peptide acts as a flag. It attracts your body's immune cells to the injection site, where they pick up the exact chemical profile of the HER2 protein and take it to the lymph nodes. ——>
1
8
Stock_profit_03
$GLSI Strs Ohio reports 94.94% increase in ownership of GLSI / Greenwich LifeSciences, Inc.
11
veggietrader
$GLSI sls should give a nice bump here. I think the word "peptide" still causes investors to be wary, and that might be less relevant now that SLS passed their trial.
10

Advertisement|Remove ads.